|
|
Blood, 1 February 2007, Vol. 109, No. 3, pp. 1307-1315.
Prepublished online as a Blood First Edition Paper on October 3, 2006; DOI 10.1182/blood-2006-05-022772.
 Previous Article | Table of Contents | Next Article 
TRANSPLANTATION
Preformed antibody, not primed T cells, is the initial and major barrier to bone marrow engraftment in allosensitized recipients
Patricia A. Taylor1,
Michael J. Ehrhardt1,
Matthew M. Roforth1,
Jessica M. Swedin1,
Angela Panoskaltsis-Mortari1,
Jonathan S. Serody2, and
Bruce R. Blazar1
1 University of Minnesota Cancer Center and Department of Pediatrics, Division of BMT, Minneapolis, MN;
2 Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC
Multiply-transfused individuals are at higher risk for BM rejection. We show that whereas allosensitization resulted in the priming of both cellular and humoral immunity, preformed antibody was the major barrier to engraftment. The generation of cross-reactive alloantibody led to rejection of BM of a different MHC-disparate strain. Imaging studies indicated that antibody-mediated rejection was very rapid (< 3 hours) in primed recipients, while T-cell–mediated rejection in nonprimed mice took more than 6 days. Antibody-mediated BM rejection was not due to a defect in BM homing as rejection occurred despite direct intra-BM infusion of donor BM. Rejection was dependent upon host FcR+ cells. BM cells incubated with serum from primed mice were eliminated in nonprimed recipients, indicating that persistent exposure to high-titer antibody was not essential for rejection. High donor engraftment was achieved in a proportion of primed mice by mega-BM cell dose, in vivo T-cell depletion, and high-dose immunoglobulin infusion. The addition of splenectomy to this protocol only modestly added to the efficacy of this combination strategy. These data demonstrate both rapid alloantibody-mediated elimination of BM by host FcR+ cells and priming of host antidonor T cells and suggest a practical strategy to overcome engraftment barriers in primed individuals.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Articles in Blood Online:
-
In situ identification of allospecific B cells using pentamers
- Angela Panoskaltsis-Mortari, Patricia A. Taylor, Megan J. Riddle, Mark A. Shlomchik, and Bruce R. Blazar
Blood 2008 111: 3904-3905.
[Full Text]
[PDF]
-
B-ware of allosensitized graft rejection
- Daniel H. Fowler
Blood 2007 109: 851-852.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
R. Storb
B cells versus T cells as primary barrier to hematopoietic engraftment in allosensitized recipients
Blood,
January 29, 2009;
113(5):
1205 - 1205.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Xu, Y. Huang, P. M. Chilton, L.-R. Hussain, M. K. Tanner, J. Yan, and S. T. Ildstad
Strategic Nonmyeloablative Conditioning: CD154:CD40 Costimulatory Blockade at Primary Bone Marrow Transplantation Promotes Engraftment for Secondary Bone Marrow Transplantation after Engraftment Failure
J. Immunol.,
November 1, 2008;
181(9):
6616 - 6624.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. A. Taylor, M. J. Ehrhardt, C. J. Lees, A. Panoskaltsis-Mortari, A. M. Krieg, A. H. Sharpe, W. J. Murphy, J. S. Serody, H. Hemmi, S. Akira, et al.
TLR agonists regulate alloresponses and uncover a critical role for donor APCs in allogeneic bone marrow rejection
Blood,
October 15, 2008;
112(8):
3508 - 3516.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Panoskaltsis-Mortari, P. A. Taylor, M. J. Riddle, M. A. Shlomchik, and B. R. Blazar
In situ identification of allospecific B cells using pentamers
Blood,
April 1, 2008;
111(7):
3904 - 3905.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Xu, J. Yan, Y. Huang, P. M. Chilton, C. Ding, C. L. Schanie, L. Wang, and S. T. Ildstad
Costimulatory blockade of CD154-CD40 in combination with T-cell lymphodepletion results in prevention of allogeneic sensitization
Blood,
March 15, 2008;
111(6):
3266 - 3275.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
